Zoetis Inc. (ZTS) stock
ZTSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3045% below fair value
$83.82+0.86 (+1.04%)
Close on Nov 13, 2026Market cap $34.64BP/E 14.1Yield 2.42%
Zoetis EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Zoetis's EPS for the twelve months ending Sep 30, 2026 was $5.93, up 0.7% year over year. For fiscal 2025 it was $6.02, up 10.1% from the year before. Over ten years it grew 24.4% a year on average. The highest annual figure on record is $6.02 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.02 | +10.1% |
| FY2024 | Dec 31, 2024 | $5.47 | +7.9% |
| FY2023 | Dec 31, 2023 | $5.07 | +12.9% |
| FY2022 | Dec 31, 2022 | $4.49 | +5.2% |
| FY2021 | Dec 31, 2021 | $4.27 | +24.9% |
| FY2020 | Dec 31, 2020 | $3.42 | +10.0% |
| FY2019 | Dec 31, 2019 | $3.11 | +6.1% |
| FY2018 | Dec 31, 2018 | $2.93 | +67.4% |
| FY2017 | Dec 31, 2017 | $1.75 | +6.1% |
| FY2016 | Dec 31, 2016 | $1.65 | +142.6% |
| FY2015 | Dec 31, 2015 | $0.68 | -41.4% |
| FY2014 | Dec 31, 2014 | $1.16 | +14.9% |
| FY2013 | Dec 31, 2013 | $1.01 | +16.1% |
| FY2012 | Dec 31, 2012 | $0.87 | +77.6% |
| FY2011 | Dec 31, 2011 | $0.49 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.44 | -11.7% |
| Q2 FY2026 | Jun 30, 2026 | $1.65 | +1.2% |
| Q1 FY2026 | Mar 31, 2026 | $1.42 | +6.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.42 | +10.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.63 | +8.7% |
| Q2 FY2025 | Jun 30, 2025 | $1.63 | +19.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.34 | +2.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.29 | +13.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.50 | +16.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.37 | -5.5% |
| Q1 FY2024 | Mar 31, 2024 | $1.31 | +10.1% |
| Q4 FY2023 | Dec 31, 2023 | $1.14 | +15.2% |
| Q3 FY2023 | Sep 30, 2023 | $1.29 | +14.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.45 | +29.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.19 | -5.6% |
| Q4 FY2022 | Dec 31, 2022 | $0.99 | +13.8% |
| Q3 FY2022 | Sep 30, 2022 | $1.13 | -2.6% |
| Q2 FY2022 | Jun 30, 2022 | $1.12 | +4.7% |
| Q1 FY2022 | Mar 31, 2022 | $1.26 | +7.7% |
| Q4 FY2021 | Dec 31, 2021 | $0.87 | +16.0% |
| Q3 FY2021 | Sep 30, 2021 | $1.16 | +16.0% |
| Q2 FY2021 | Jun 30, 2021 | $1.07 | +35.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.17 | +33.0% |
| Q4 FY2020 | Dec 31, 2020 | $0.75 | -6.3% |
| Q3 FY2020 | Sep 30, 2020 | $1.00 | +11.1% |
| Q2 FY2020 | Jun 30, 2020 | $0.79 | +2.6% |
| Q1 FY2020 | Mar 31, 2020 | $0.88 | +35.4% |
| Q4 FY2019 | Dec 31, 2019 | $0.80 | +12.7% |
| Q3 FY2019 | Sep 30, 2019 | $0.90 | +26.8% |
| Q2 FY2019 | Jun 30, 2019 | $0.77 | -2.5% |
| Q1 FY2019 | Mar 31, 2019 | $0.65 | -9.7% |
| Q4 FY2018 | Dec 31, 2018 | $0.71 | +343.8% |
| Q3 FY2018 | Sep 30, 2018 | $0.71 | +16.4% |
| Q2 FY2018 | Jun 30, 2018 | $0.79 | +58.0% |
| Q1 FY2018 | Mar 31, 2018 | $0.72 | +50.0% |
| Q4 FY2017 | Dec 31, 2017 | $0.16 | -48.4% |
| Q3 FY2017 | Oct 1, 2017 | $0.61 | – |
| Q2 FY2017 | Jul 2, 2017 | $0.50 | – |
| Q1 FY2017 | Apr 2, 2017 | $0.48 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.31 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?